# Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia

> **NCT00773149** · PHASE1,PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 12 (actual)

## Conditions studied

- Acute Lymphocytic Leukemia

## Interventions

- **DRUG:** Alemtuzumab (CAMPATH 1H) associated to G-CSF

## Key facts

- **NCT ID:** NCT00773149
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-10
- **Primary completion:** 2011-01
- **Final completion:** 2011-07
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2012-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00773149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00773149, "Alemtuzumab (CAMPATH 1H) Associated to G-CSF in Adult Patients With Refractory Acute Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00773149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*